Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2015

01-09-2015 | Letter to the Editor

Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma

Authors: Chan Yoon Cheah, Robert Z. Orlowski, Elisabet E. Manasanch, Thein H. Oo

Published in: Annals of Hematology | Issue 9/2015

Login to get access

Excerpt

Dear Editor, …
Literature
1.
George JN (2015) Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion 55:11–13PubMedCrossRef
2.
Ferrari S, Scheiflinger F, Rieger M et al (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109:2815–2822PubMed
3.
Kornacker M, Luft T, Ho AD et al (2005) Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases. Eur J Haematol 74:250–253PubMedCrossRef
4.
Gallerani E, Lerch E, Romagnani E et al (2006) Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 77:527–529PubMedCrossRef
5.
Munoz J, Hughes A (2012) Thrombotic thrombocytopenic purpura after autologous peripheral stem cell transplantation. Blood 119:5620PubMedCrossRef
6.
Nakamura Y, Mitani N, Ishii A et al (2013) Idiopathic pneumonia syndrome with thrombotic microangiopathy-related changes after allogeneic hematopoietic stem cell transplantation. Int J Hematol 98:496–498PubMedCrossRef
7.
Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V et al (2013) Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 161:279–280PubMedCrossRef
8.
Morita R, Hashino S, Shirai S et al (2008) Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 88:248–250PubMedCrossRef
9.
Moore H, Romeril K (2011) Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 41:348–350PubMedCrossRef
10.
Mehta N, Saxena A, Niesvizky R (2012) Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep: 2012
11.
Salmenniemi U, Remes K (2012) Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 4:e13PubMedCentralPubMed
12.
Chan KL, Filshie R, Nandurkar H et al. (2015) Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lymphoma:1–2
13.
Hobeika L, Self SE, Velez JC (2014) Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 15:156PubMedCentralPubMedCrossRef
14.
Sullivan MR, Danilov AV, Lansigan F et al. (2014) Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher
15.
Xu B, Ritchie D (2010) Thrombotic thrombocytopenic purpura associated with disseminated varicella zoster in a multiple myeloma patient. Intern Med J 40:e7–e8PubMedCrossRef
16.
Xiao X, Zhong HY, Zhang GS et al (2013) Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma. J Thromb Thrombolysis 36:422–423PubMedCrossRef
17.
Lechner K, Obermeier HL (2012) Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 91:195–205CrossRef
18.
Metadata
Title
Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma
Authors
Chan Yoon Cheah
Robert Z. Orlowski
Elisabet E. Manasanch
Thein H. Oo
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2421-0

Other articles of this Issue 9/2015

Annals of Hematology 9/2015 Go to the issue

Letter to the Editor

Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro

Letter to the Editor

Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge

Letter to the Editor

Negative PET: no guarantee of good prognosis in Hodgkin’s lymphoma

Letter to the Editor

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia

Original Article

Headache prevalence following recovery from TTP and aHUS

Original Article

Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits